

George G Zhanel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3945909/publications.pdf>

Version: 2024-02-01

312
papers

14,553
citations

22153

59
h-index

29157

104
g-index

317
all docs

317
docs citations

317
times ranked

12020
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative Review of the Carbapenems. <i>Drugs</i> , 2007, 67, 1027-1052.	10.9	484
2	Ceftazidime-Avibactam: a Novel Cephalosporin/ β -lactamase Inhibitor Combination. <i>Drugs</i> , 2013, 73, 159-177.	10.9	362
3	A Critical Review of the Fluoroquinolones. <i>Drugs</i> , 2002, 62, 13-59.	10.9	303
4	Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature. <i>Clinical Infectious Diseases</i> , 2003, 36, 1404-1410.	5.8	298
5	Imipenem+Relebactam and Meropenem+Vaborbactam: Two Novel Carbapenem- β -Lactamase Inhibitor Combinations. <i>Drugs</i> , 2018, 78, 65-98.	10.9	291
6	New Lipoglycopeptides. <i>Drugs</i> , 2010, 70, 859-886.	10.9	280
7	Ceftolozane/Tazobactam: A Novel Cephalosporin/ β -Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli. <i>Drugs</i> , 2014, 74, 31-51.	10.9	279
8	Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. <i>Drugs</i> , 2019, 79, 271-289.	10.9	274
9	The Glycylcyclines. <i>Drugs</i> , 2004, 64, 63-88.	10.9	264
10	Review of Macrolides and Ketolides. <i>Drugs</i> , 2001, 61, 443-498.	10.9	249
11	Epidemic Clonal Groups of <i>Escherichia coli</i> as a Cause of Antimicrobial-Resistant Urinary Tract Infections in Canada, 2002 to 2004. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2733-2739.	3.2	249
12	<i>Streptococcus pneumoniae</i> : Epidemiology, Risk Factors, and Strategies for Prevention. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2009, 30, 189-209.	2.1	233
13	<i>Streptococcus pneumoniae</i> : epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, 1.	2.6	219
14	Antibiotic resistance in <i>Escherichia coli</i> outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). <i>International Journal of Antimicrobial Agents</i> , 2006, 27, 468-475.	2.5	218
15	Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?. <i>Clinical Microbiology Reviews</i> , 2018, 31, .	13.6	218
16	Antimicrobial-Resistant Pathogens in Intensive Care Units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) Study, 2005-2006. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1430-1437.	3.2	207
17	Clinical Practice Guidelines for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia in Adults. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2008, 19, 19-53.	1.9	203
18	Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. <i>Drugs</i> , 2016, 76, 567-588.	10.9	199

#	ARTICLE	IF	CITATIONS
19	Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Review of Anti-Infective Therapy, 2012, 10, 459-473.	4.4	171
20	The Ketolides. Drugs, 2002, 62, 1771-1804.	10.9	165
21	Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). International Journal of Antimicrobial Agents, 2005, 26, 380-388.	2.5	165
22	Antimicrobial Resistance in Hospital-Acquired Gram-Negative Bacterial Infections. Chest, 2015, 147, 1413-1421.	0.8	155
23	A Canadian National Surveillance Study of Urinary Tract Isolates from Outpatients: Comparison of the Activities of Trimethoprim-Sulfamethoxazole, Ampicillin, Mecillinam, Nitrofurantoin, and Ciprofloxacin. Antimicrobial Agents and Chemotherapy, 2000, 44, 1089-1092.	3.2	148
24	Antimicrobial Resistance in Respiratory Tract Streptococcus pneumoniae Isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrobial Agents and Chemotherapy, 2003, 47, 1867-1874.	3.2	148
25	Fluoroquinolone-Resistant Urinary Isolates of Escherichia coli from Outpatients Are Frequently Multidrug Resistant: Results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance Study. Antimicrobial Agents and Chemotherapy, 2006, 50, 2251-2254.	3.2	140
26	Tedizolid: A Novel Oxazolidinone with Potent Activity Against Multidrug-Resistant Gram-Positive Pathogens. Drugs, 2015, 75, 253-270.	10.9	140
27	Prevalence of Antimicrobial-Resistant Pathogens in Canadian Hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrobial Agents and Chemotherapy, 2010, 54, 4684-4693.	3.2	138
28	Molecular epidemiology of extended-spectrum β -lactamase-, AmpC β -lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. Journal of Antimicrobial Chemotherapy, 2013, 68, i57-i65.	3.0	131
29	Oritavancin: Mechanism of Action. Clinical Infectious Diseases, 2012, 54, S214-S219.	5.8	124
30	Piperacillin-tazobactam: a β -lactam/ β -lactamase inhibitor combination. Expert Review of Anti-Infective Therapy, 2007, 5, 365-383.	4.4	115
31	Ceftaroline. Drugs, 2009, 69, 809-831.	10.9	114
32	Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study. Journal of Antimicrobial Chemotherapy, 2013, 68, i7-i22.	3.0	114
33	<i>Streptococcus pneumoniae</i> : Does Antimicrobial Resistance Matter?. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 210-238.	2.1	110
34	Evolution of antimicrobial resistance among Enterobacteriaceae (focus on extended spectrum) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 14	1.8	99
35	Serotype distribution of invasive <i>Streptococcus pneumoniae</i> in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012. Canadian Journal of Microbiology, 2013, 59, 778-788.	1.7	99
36	Antimicrobial Resistance in Urinary Tract Pathogens in Canada from 2007 to 2009: CANWARD Surveillance Study. Antimicrobial Agents and Chemotherapy, 2011, 55, 3169-3175.	3.2	97

#	ARTICLE	IF	CITATIONS
37	The Postantibiotic Effect: A Review of in Vitro and in Vivo Data. DICP: the Annals of Pharmacotherapy, 1991, 25, 153-163.	0.2	94
38	The New Fluoroquinolones: A Critical Review. Canadian Journal of Infectious Diseases & Medical Microbiology, 1999, 10, 207-238.	0.3	90
39	Prevalence of Antimicrobial Resistance in Respiratory Tract Isolates of Streptococcus pneumoniae : Results of a Canadian National Surveillance Study. Antimicrobial Agents and Chemotherapy, 1999, 43, 2504-2509.	3.2	88
40	Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrobial Agents and Chemotherapy, 2002, 46, 1295-1301.	3.2	86
41	Antimicrobial Resistance in Haemophilus influenzae and Moraxella catarrhalis Respiratory Tract Isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrobial Agents and Chemotherapy, 2003, 47, 1875-1881.	3.2	85
42	Macrolide-Resistant Streptococcus pneumoniae in Canada during 1998-1999: Prevalence of mef (A) and erm (B) and Susceptibilities to Ketolides. Antimicrobial Agents and Chemotherapy, 2001, 45, 2147-2150.	3.2	81
43	Adjuvants Based on Hybrid Antibiotics Overcome Resistance in <i>Pseudomonas aeruginosa</i> and Enhance Fluoroquinolone Efficacy. Angewandte Chemie - International Edition, 2016, 55, 555-559.	13.8	80
44	Pharmacokinetic Contributions to Postantibiotic Effects. Clinical Pharmacokinetics, 1994, 27, 377-392.	3.5	77
45	Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS). Journal of Antimicrobial Chemotherapy, 2003, 52, 382-388.	3.0	77
46	Tigecycline: a novel glycylcycline antibiotic. Expert Review of Anti-Infective Therapy, 2006, 4, 9-25.	4.4	77
47	Anti-infective research and development—problems, challenges, and solutions. Lancet Infectious Diseases, The, 2007, 7, 68-78.	9.1	76
48	Antibacterial Activities of Aminoglycoside Antibiotics-Derived Cationic Amphiphiles. Polyol-Modified Neomycin B-, Kanamycin A-, Amikacin-, and Neamine-Based Amphiphiles with Potent Broad Spectrum Antibacterial Activity. Journal of Medicinal Chemistry, 2010, 53, 3626-3631.	6.4	76
49	Ertapenem: review of a new carbapenem. Expert Review of Anti-Infective Therapy, 2005, 3, 23-39.	4.4	75
50	Vancomycin-Resistant Enterococci. Annals of Pharmacotherapy, 1996, 30, 615-624.	1.9	72
51	Escalation of Antimicrobial Resistance among Streptococcus pneumoniae: Implications for Therapy. Seminars in Respiratory and Critical Care Medicine, 2005, 26, 575-616.	2.1	71
52	Ceftobiprole. American Journal of Clinical Dermatology, 2008, 9, 245-254.	6.7	71
53	Telavancin: Mechanisms of Action, In Vitro Activity, and Mechanisms of Resistance. Clinical Infectious Diseases, 2015, 61, S58-S68.	5.8	71
54	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. Journal of Medicinal Chemistry, 2017, 60, 3684-3702.	6.4	71

#	ARTICLE	IF	CITATIONS
55	Hybrid Antibiotic Overcomes Resistance in <i>P. aeruginosa</i> by Enhancing Outer Membrane Penetration and Reducing Efflux. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 8441-8455.	6.4	70
56	A Review of New Fluoroquinolones. <i>Treatments in Respiratory Medicine</i> , 2006, 5, 437-465.	1.4	67
57	In Vitro Activity of Nemonoxacin, a Novel Nonfluorinated Quinolone, against 2,440 Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4915-4920.	3.2	67
58	Characterization of MDR and XDR <i>Streptococcus pneumoniae</i> in Canada, 2007-2013. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2199-2202.	3.0	65
59	Stretching the mutant prevention concentration (MPC) beyond its limits. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 1323-1325.	3.0	62
60	Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 69, 291-306.	1.8	62
61	Candidemia in a Canadian tertiary care hospital from 1976 to 1996. <i>Diagnostic Microbiology and Infectious Disease</i> , 1997, 29, 5-9.	1.8	60
62	In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 55-62.	1.8	60
63	Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. <i>Drugs</i> , 2020, 80, 285-313.	10.9	60
64	Fidaxomicin: A Novel Agent for the Treatment of <i>Clostridium difficile</i> Infection. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2015, 26, 305-312.	1.9	59
65	In Vitro Susceptibilities of <i>Candida</i> and <i>Cryptococcus neoformans</i> Isolates from Blood Cultures of Neutropenic Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 1463-1464.	3.2	58
66	Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2016, 2016, 1-10.	1.9	58
67	Horizontal transfer of antibiotic resistance from <i>Enterococcus faecium</i> of fermented meat origin to clinical isolates of <i>E. faecium</i> and <i>Enterococcus faecalis</i> . <i>International Journal of Food Microbiology</i> , 2015, 199, 78-85.	4.7	57
68	A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3913-3932.	6.4	57
69	A review of clinical failures associated with macrolide-resistant <i>Streptococcus pneumoniae</i> . <i>International Journal of Antimicrobial Agents</i> , 2004, 24, 95-104.	2.5	56
70	Comparison of community-associated and health care-associated methicillin-resistant <i>Staphylococcus aureus</i> in Canada: results of the CANWARD 2007-2009 study. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 69, 320-325.	1.8	56
71	Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections. <i>Expert Review of Anti-Infective Therapy</i> , 2008, 6, 67-81.	4.4	55
72	Antibacterial activity of guanidinylated neomycin B- and kanamycin A-derived amphiphilic lipid conjugates. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1224-1227.	3.0	55

#	ARTICLE	IF	CITATIONS
73	Prevalence and characterization of extended-spectrum β -lactamase ⁺ and AmpC β -lactamase ⁺ producing <i>Escherichia coli</i> : results of the CANWARD 2007-2009 study. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 69, 326-334.	1.8	55
74	Microbiology and Preclinical Review of Omadacycline. <i>Clinical Infectious Diseases</i> , 2019, 69, S6-S15.	5.8	55
75	Imipenem and Meropenem: Comparison of In Vitro Activity, Pharmacokinetics, Clinical Trials and Adverse Effects. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 1998, 9, 215-228.	0.3	53
76	Evaluation of amphiphilic aminoglycoside-peptide triazole conjugates as antibacterial agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 3031-3035.	2.2	53
77	Influence of Human Serum on Antifungal Pharmacodynamics with <i>Candida albicans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 2018-2022.	3.2	51
78	Faropenem: review of a new oral penem. <i>Expert Review of Anti-Infective Therapy</i> , 2007, 5, 185-198.	4.4	51
79	Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of <i>Acne Vulgaris</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	50
80	Role of efflux mechanisms on fluoroquinolone resistance in <i>Streptococcus pneumoniae</i> and <i>Pseudomonas aeruginosa</i> . <i>International Journal of Antimicrobial Agents</i> , 2004, 24, 529-535.	2.5	49
81	Molecular Characterization of Increasing Fluoroquinolone Resistance in <i>Streptococcus pneumoniae</i> Isolates in Canada, 1997 to 2005. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 198-207.	3.2	49
82	Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 62, 67-80.	1.8	49
83	Characterization of plasmids encoding CMY-2 AmpC β -lactamases from <i>Escherichia coli</i> in Canadian intensive care units. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 65, 379-383.	1.8	49
84	Infections Due to <i>Acinetobacter baumannii</i> in the ICU: Treatment Options. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 311-325.	2.1	49
85	The Anthelmintic Drug Niclosamide Synergizes with Colistin and Reverses Colistin Resistance in Gram-Negative Bacilli. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	49
86	Analysis of multidrug resistance in the predominant <i>Streptococcus pneumoniae</i> serotypes in Canada: the SAVE study, 2011-15. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, vii12-vii19.	3.0	48
87	Penicillin-Binding Protein 1A, 2B, and 2X Alterations in Canadian Isolates of Penicillin-Resistant <i>Streptococcus pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3261-3264.	3.2	47
88	Molecular characterization of fluoroquinolone resistant <i>Streptococcus pneumoniae</i> clinical isolates obtained from across Canada. <i>Diagnostic Microbiology and Infectious Disease</i> , 2003, 45, 63-67.	1.8	47
89	Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 343-349.	3.0	47
90	Antibacterial Activity of Ultrashort Cationic Lipo- β -Peptides. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2215-2217.	3.2	46

#	ARTICLE	IF	CITATIONS
91	Prevalence of antimicrobial resistant pathogens from blood cultures from Canadian hospitals: results of the CANWARD 2007–2009 study. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 69, 307-313.	1.8	46
92	Mutant Prevention Concentrations for Single-Step Fluoroquinolone-Resistant Mutants of Wild-Type, Efflux-Positive, or ParC or GyrA Mutation-Containing <i>Streptococcus pneumoniae</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3954-3958.	3.2	44
93	Mutant Prevention Concentrations of Levofloxacin Alone and in Combination with Azithromycin, Cefazidime, Colistin (Polymyxin E), Meropenem, Piperacillin-Tazobactam, and Tobramycin against <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2228-2230.	3.2	44
94	Pharmacodynamic Modeling of Clarithromycin against Macrolide-Resistant [PCR-Positive <i>mef</i> (A) or <i>erm</i> (B)] <i>Streptococcus pneumoniae</i> Simulating Clinically Achievable Serum and Epithelial Lining Fluid Free-Drug Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 4029-4034.	3.2	43
95	Dual activity of fluoroquinolones against <i>Streptococcus pneumoniae</i> : the facts behind the claims. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 49, 893-895.	3.0	43
96	In Vitro Activity of Ceftaroline against Gram-Positive and Gram-Negative Pathogens Isolated from Patients in Canadian Hospitals in 2009. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2837-2846.	3.2	43
97	Biocide Selective TolC-Independent Efflux Pumps in Enterobacteriaceae. <i>Journal of Membrane Biology</i> , 2018, 251, 15-33.	2.1	43
98	42936 pathogens from Canadian hospitals: 10 years of results (2007–16) from the CANWARD surveillance study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, iv5-iv21.	3.0	43
99	In Vitro Activity of Fosfomycin against <i>Escherichia coli</i> Isolated from Patients with Urinary Tract Infections in Canada as Part of the CANWARD Surveillance Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1252-1256.	3.2	42
100	Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, i31-i37.	3.0	41
101	Triclosan Can Select for an <i>AdelJK</i> -Overexpressing Mutant of <i>Acinetobacter baumannii</i> ATCC 17978 That Displays Reduced Susceptibility to Multiple Antibiotics. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6424-6431.	3.2	41
102	Emergence of Antimicrobial Resistance among <i>Pseudomonas aeruginosa</i> : Implications for Therapy. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 326-345.	2.1	41
103	In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of <i>Streptococcus pneumoniae</i> , <i>Haemophilus influenzae</i> , and <i>Moraxella catarrhalis</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 1999, 35, 37-44.	1.8	40
104	Canadian Practice Guidelines for Surgical Intra-Abdominal Infections. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2010, 21, 11-37.	1.9	40
105	Antibacterial activity of amphiphilic tobramycin. <i>Journal of Antibiotics</i> , 2012, 65, 495-498.	2.0	40
106	Changing epidemiology of methicillin-resistant <i>Staphylococcus aureus</i> in Canada. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, i47-i55.	3.0	40
107	Uncomplicated urinary tract infection in women. Current practice and the effect of antibiotic resistance on empiric treatment. <i>Canadian Family Physician</i> , 2006, 52, 612-8.	0.4	40
108	Influence of pharmacokinetic and pharmacodynamic principles on antibiotic selection. <i>Current Infectious Disease Reports</i> , 2001, 3, 29-34.	3.0	38

#	ARTICLE	IF	CITATIONS
109	Antibiotic Resistance and Expression Of Resistance-Nodulation-Division Pump- and Outer Membrane Porin-Encoding Genes in <i>Acinetobacter</i> Species Isolated from Canadian Hospitals. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2013, 24, 17-21.	1.9	38
110	Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia. <i>Drugs</i> , 2016, 76, 1737-1757.	10.9	38
111	Nitrofurantoin Is Active against Vancomycin-Resistant Enterococci. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 324-326.	3.2	37
112	Pharmacodynamic target attainment analysis against <i>Streptococcus pneumoniae</i> using levofloxacin 500mg, 750mg and 1000mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). <i>International Journal of Antimicrobial Agents</i> , 2004, 24, 479-484.	2.5	37
113	Synthesis and antibacterial activity of amphiphilic lysine-ligated neomycin B conjugates. <i>Carbohydrate Research</i> , 2011, 346, 560-568.	2.3	37
114	Antimicrobial susceptibility of 2906 <i>Pseudomonas aeruginosa</i> clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: Results of the Canadian Ward surveillance study (CANWARD), 2008-2015. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 87, 60-63.	1.8	36
115	Dramatic rise in the proportion of ESBL-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, iv64-iv71.	3.0	36
116	In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 97, 115012.	1.8	36
117	Comparative Analysis of Outer Membrane Vesicle Isolation Methods With an <i>Escherichia coli</i> <i>tolA</i> Mutant Reveals a Hypervesiculating Phenotype With Outer-Inner Membrane Vesicle Content. <i>Frontiers in Microbiology</i> , 2021, 12, 628801.	3.5	36
118	Musculoskeletal Injury Associated with Fluoroquinolone Antibiotics. <i>Clinics in Plastic Surgery</i> , 2005, 32, 495-502.	1.5	35
119	Antibacterial Use in Community Practice. <i>Drugs</i> , 1999, 57, 871-881.	10.9	34
120	Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant <i>Streptococcus pneumoniae</i> simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 83-88.	3.0	34
121	Mechanisms of resistance and mobility among multidrug-resistant CTX-M β -producing <i>Escherichia coli</i> from Canadian intensive care units: the 1st report of QepA in North America. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 63, 319-326.	1.8	34
122	Trends in antibiotic resistance over time among pathogens from Canadian hospitals: results of the CANWARD study 2007-11. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, i23-i29.	3.0	34
123	Repurposed Antimicrobial Combination Therapy: Tobramycin-Ciprofloxacin Hybrid Augments Activity of the Anticancer Drug Mitomycin C Against Multidrug-Resistant Gram-Negative Bacteria. <i>Frontiers in Microbiology</i> , 2019, 10, 1556.	3.5	34
124	Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant <i>Streptococcus pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 49, 807-812.	3.0	33
125	Regenerability of antibacterial activity of interpenetrating polymeric <i>N</i> -halamine and poly(ethylene terephthalate). <i>Journal of Applied Polymer Science</i> , 2011, 120, 611-622.	2.6	33
126	In Vitro Activity of Ceftaroline-Avibactam against Gram-Negative and Gram-Positive Pathogens Isolated from Patients in Canadian Hospitals from 2010 to 2012: Results from the CANWARD Surveillance Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5600-5611.	3.2	32

#	ARTICLE	IF	CITATIONS
127	In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007â€“2009 study. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 69, 342-347.	1.8	31
128	Investigating the antimicrobial peptide â€“window of activityâ€™ using cationic lipopeptides with hydrocarbon and fluorinated tails. <i>International Journal of Antimicrobial Agents</i> , 2012, 40, 36-42.	2.5	31
129	Assessment of multidrug resistance, clonality and virulence in non-PCV-13 <i>Streptococcus pneumoniae</i> serotypes in Canada, 2011-13. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1960-4.	3.0	31
130	Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2018, 2018, 1-13.	1.9	31
131	Comparison of Antimicrobial Resistance Profiles among Extended-Spectrum-Î²-Lactamase-Producing and Acquired AmpC Î²-Lactamase-Producing <i>Escherichia coli</i> Isolates from Canadian Intensive Care Units. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1846-1849.	3.2	30
132	In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007â€“2009 study. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 69, 348-355.	1.8	30
133	Potential of Î²-lactam antibiotics and Î²-lactam/Î²-lactamase inhibitor combinations against MDR and XDR <i>Pseudomonas aeruginosa</i> using non-ribosomal tobramycinâ€“cyclam conjugates. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2640-2648.	3.0	30
134	Subinhibitory Antimicrobial Concentrations: A Review of In Vitro and In Vivo Data. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 1992, 3, 193-201.	0.3	29
135	Annual macrolide prescription rates and the emergence of macrolide resistance among <i>Streptococcus pneumoniae</i> in Canada from 1995 to 2005. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 375-379.	2.5	29
136	Changes in fluoroquinolone resistance over 5 years (CANWARD 2007-11) in bacterial pathogens isolated in Canadian hospitals. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, i39-i46.	3.0	29
137	Evolution and molecular characterization of macrolide-resistant <i>Streptococcus pneumoniae</i> in Canada between 1998 and 2008. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 59-66.	3.0	29
138	Influence of Human Serum on Pharmacodynamic Properties of an Investigational Glycopeptide, LY333328, and Comparator Agents against <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 2427-2430.	3.2	28
139	Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on <i>S. pneumoniae</i> . <i>Expert Opinion on Emerging Drugs</i> , 2003, 8, 297-321.	2.4	28
140	Invasive <i>Streptococcus pneumoniae</i> in Canada, 2011â€“2014: Characterization of new candidate 15-valent pneumococcal conjugate vaccine serotypes 22F and 33F. <i>Vaccine</i> , 2016, 34, 2527-2530.	3.8	28
141	Short Proline-Rich Lipopeptide Potentiates Minocycline and Rifampin against Multidrug- and Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	28
142	Synergistic combinations of anthelmintic salicylanilides oxyclozanide, rafoxanide, and closantel with colistin eradicates multidrug-resistant colistin-resistant Gram-negative bacilli. <i>Journal of Antibiotics</i> , 2019, 72, 605-616.	2.0	28
143	Susceptibility of Community Gram-Negative Urinary Tract Isolates to Mecillinam and Other Oral Agents. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 2001, 12, 289-292.	0.3	27
144	Mechanisms of resistance to telithromycin in <i>Streptococcus pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 447-450.	3.0	27

#	ARTICLE	IF	CITATIONS
145	Molecular characterization of predominant <i>Streptococcus pneumoniae</i> serotypes causing invasive infections in Canada: the SAVE study, 2011–15. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, vii20-vii31.	3.0	27
146	Species distribution and antifungal susceptibility of invasive <i>Candida</i> isolates from Canadian hospitals: results of the CANWARD 2011–16 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, iv48-iv54.	3.0	27
147	Heterodimeric Rifampicin–Tobramycin conjugates break intrinsic resistance of <i>Pseudomonas aeruginosa</i> to doxycycline and chloramphenicol <i>in vitro</i> and in a <i>Galleria mellonella</i> <i>in vivo</i> model. <i>European Journal of Medicinal Chemistry</i> , 2019, 174, 16-32.	5.5	27
148	Screening of Stool Samples for Identification of Vancomycin-Resistant Enterococcus Isolates Should Include the Methyl- β -D-Glucopyranoside Test To Differentiate Nonmotile <i>Enterococcus gallinarum</i> from <i>E. faecium</i> . <i>Journal of Clinical Microbiology</i> , 1998, 36, 2333-2335.	3.9	27
149	Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant <i>Staphylococcus aureus</i> (MRSA), vancomycin-intermediate <i>Staphylococcus aureus</i> (VISA) and vancomycin-resistant <i>Staphylococcus aureus</i> (VRSA) using an <i>in vitro</i> model. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 364-369.	3.0	26
150	Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit–isolated methicillin-resistant <i>Staphylococcus aureus</i> . <i>Clinical and Experimental Pharmacology and Physiology</i> , 2014, 41, 437-443.	1.9	26
151	Polymyxin B–Tobramycin Hybrids with <i>Pseudomonas aeruginosa</i> -Selective Antibacterial Activity and Strong Potentiation of Rifampicin, Minocycline, and Vancomycin. <i>ACS Infectious Diseases</i> , 2017, 3, 941-954.	3.8	26
152	Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant <i>Escherichia coli</i> . <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2018, 2018, 1-9.	1.9	26
153	Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 645-653.	3.0	26
154	Guanidylation and Tail Effects in Cationic Antimicrobial Lipopeptides. <i>PLoS ONE</i> , 2012, 7, e41141.	2.5	26
155	Molecular Epidemiology of Penicillin-Resistant and Ciprofloxacin-Resistant <i>Streptococcus pneumoniae</i> in Canada. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 804-808.	3.2	25
156	Expression of the <i>mef</i> (E) Gene Encoding the Macrolide Efflux Pump Protein Increases in <i>Streptococcus pneumoniae</i> with Increasing Resistance to Macrolides. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4635-4640.	3.2	25
157	Characterization of Methicillin-Resistant <i>Staphylococcus aureus</i> , Vancomycin-Resistant Enterococci and Extended-Spectrum Beta-Lactamase-Producing <i>Escherichia coli</i> in Intensive Care Units in Canada: Results of the Canadian National Intensive Care Unit (Can-Icu) Study (2005–2006). <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2008, 19, 243-249.	1.9	25
158	Synthesis and Antibacterial Activities of Amphiphilic Neomycin B-based Bilipid Conjugates and Fluorinated Neomycin B-based Lipids. <i>Molecules</i> , 2012, 17, 9129-9141.	3.8	25
159	Neomycin–phenolic conjugates: Polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 1499-1503.	2.2	25
160	Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant <i>Streptococcus pneumoniae</i> : analysis of Phase 3 clinical trial data. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2835-2840.	3.0	25
161	Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for <i>Streptococcus pneumoniae</i> . <i>International Journal of Antimicrobial Agents</i> , 2005, 26, 120-125.	2.5	24
162	Molecular characterisation of Canadian paediatric multidrug-resistant <i>Streptococcus pneumoniae</i> from 1998–2004. <i>International Journal of Antimicrobial Agents</i> , 2006, 28, 465-471.	2.5	24

#	ARTICLE	IF	CITATIONS
163	Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant <i>Staphylococcus aureus</i> , heteroresistant vancomycin-intermediate <i>S. aureus</i> , vancomycin-intermediate <i>S. aureus</i> and vancomycin-resistant <i>S. aureus</i> using an in vitro model. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1301-1305.	3.0	24
164	Frequency of MCR-1-mediated colistin resistance among <i>Escherichia coli</i> clinical isolates obtained from patients in Canadian hospitals (CANWARD 2008-2015). <i>CMAJ Open</i> , 2016, 4, E641-E645.	2.4	24
165	Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 9103-9115.	6.4	24
166	Multidrug-resistant North American pulsotype 2 <i>Clostridium difficile</i> was the predominant toxigenic hospital-acquired strain in the province of Manitoba, Canada, in 2006–2007. <i>Journal of Medical Microbiology</i> , 2012, 61, 693-700.	1.8	24
167	Antibiotic Use in a Canadian Province, 1995–1998. <i>Annals of Pharmacotherapy</i> , 2000, 34, 459-464.	1.9	23
168	Overview of Seizure-Inducing Potential of Doripenem. <i>Drug Safety</i> , 2009, 32, 709-716.	3.2	23
169	Genomic Characterization of Ciprofloxacin Resistance in a Laboratory-Derived Mutant and a Clinical Isolate of <i>Streptococcus pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4911-4919.	3.2	23
170	Role of glycoside hydrolase genes in sinigrin degradation by <i>E. coli</i> O157:H7. <i>International Journal of Food Microbiology</i> , 2015, 205, 105-111.	4.7	23
171	PCR ribotyping and antimicrobial susceptibility testing of isolates of <i>Clostridium difficile</i> cultured from toxin-positive diarrheal stools of patients receiving medical care in Canadian hospitals: the Canadian <i>Clostridium difficile</i> Surveillance Study (CAN-DIFF) 2013–2015. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 105-111.	1.8	23
172	Serotype distribution of invasive <i>Streptococcus pneumoniae</i> in adults 65+ years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010–2016. <i>Vaccine</i> , 2018, 36, 4701-4707.	3.8	23
173	Tobramycin-Linked Efflux Pump Inhibitor Conjugates Synergize Fluoroquinolones, Rifampicin and Fosfomycin against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> . <i>Journal of Clinical Medicine</i> , 2018, 7, 158.	2.4	23
174	Characterization of carbapenem-resistant and XDR <i>Pseudomonas aeruginosa</i> in Canada: results of the CANWARD 2007–16 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, iv32-iv38.	3.0	23
175	Vancomycin-resistant enterococci (VRE) colonization of high-risk patients in tertiary care Canadian hospitals. <i>Diagnostic Microbiology and Infectious Disease</i> , 1999, 35, 1-7.	1.8	22
176	Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant <i>Streptococcus pneumoniae</i> simulating clinically achievable free serum and epithelial lining fluid concentrations. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 1072-1077.	3.0	22
177	Pharmacodynamic Activity of Telithromycin at Simulated Clinically Achievable Free-Drug Concentrations in Serum and Epithelial Lining Fluid against Efflux (<i>mefE</i>)-Producing Macrolide-Resistant <i>Streptococcus pneumoniae</i> for Which Telithromycin MICs Vary. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1943-1948.	3.2	22
178	Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum- β -lactamase-producing <i>Escherichia coli</i> with amoxicillin/clavulanate: case report and characterization of the isolate. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 1262-1263.	3.0	22
179	Structure–activity relationships in ultrashort cationic lipopeptides: the effects of amino acid ring constraint on antibacterial activity. <i>Amino Acids</i> , 2014, 46, 2517-2530.	2.7	22
180	Analysis of 3789 in- and outpatient <i>Escherichia coli</i> isolates from across Canada—results of the CANWARD 2007–2009 study. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 69, 314-319.	1.8	21

#	ARTICLE	IF	CITATIONS
181	Phylogenetic analysis of emergent <i>Streptococcus pneumoniae</i> serotype 22F causing invasive pneumococcal disease using whole genome sequencing. <i>PLoS ONE</i> , 2017, 12, e0178040.	2.5	21
182	In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible <i>Pseudomonas aeruginosa</i> clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008–16. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 703-708.	3.0	21
183	Comparison of antimicrobial resistance patterns in <i>Streptococcus pneumoniae</i> from respiratory and blood cultures in Canadian hospitals from 2007–16. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, iv39-iv47.	3.0	21
184	In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of <i>Escherichia coli</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	20
185	Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. <i>Drugs</i> , 2021, 81, 233-256.	10.9	20
186	A Critical Review of Oxazolidinones: An Alternative or Replacement for Glycopeptides and Streptogramins?. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 2001, 12, 379-390.	0.3	19
187	Pharmacodynamic target attainment potential of azithromycin, clarithromycin, and telithromycin in serum and epithelial lining fluid of community-acquired pneumonia patients with penicillin-susceptible, intermediate, and resistant <i>Streptococcus pneumoniae</i> . <i>International Journal of Infectious Diseases</i> , 2009, 13, 483-487.	3.3	19
188	Baseline Epidemiology of <i>Streptococcus pneumoniae</i> Serotypes in Canada Prior to the Introduction of the 13-Valent Pneumococcal Vaccine. <i>Microbial Drug Resistance</i> , 2012, 18, 176-182.	2.0	19
189	Characterization of MRSA in Canada from 2007 to 2016. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, iv55-iv63.	3.0	19
190	Amphiphilic nebramine-based hybrids Rescue legacy antibiotics from intrinsic resistance in multidrug-resistant Gram-negative bacilli. <i>European Journal of Medicinal Chemistry</i> , 2019, 175, 187-200.	5.5	19
191	<i>In Vitro</i> Activity of Plazomicin against Gram-Negative and Gram-Positive Bacterial Pathogens Isolated from Patients in Canadian Hospitals from 2013 to 2017 as Part of the CANWARD Surveillance Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	19
192	Dilipid ultrashort cationic lipopeptides as adjuvants for chloramphenicol and other conventional antibiotics against Gram-negative bacteria. <i>Amino Acids</i> , 2019, 51, 383-393.	2.7	19
193	Escalating antimicrobial resistance among Enterobacteriaceae: focus on carbapenemases. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1455-1474.	1.8	19
194	Clinical implications of macrolide resistance in community-acquired respiratory tract infections. <i>Expert Review of Anti-Infective Therapy</i> , 2006, 4, 973-980.	4.4	18
195	Limitations of ceftriaxone compared with cefazolin against MSSA: an integrated pharmacodynamic analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1888-1894.	3.0	18
196	ESBL Genotypes in Fluoroquinolone-Resistant and Fluoroquinolone-Susceptible ESBL-Producing <i>Escherichia coli</i> Urinary Isolates in Manitoba. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2007, 18, 133-137.	1.9	17
197	Antimicrobial susceptibility testing of invasive isolates of <i>Streptococcus pneumoniae</i> from Canadian patients: the SAVE study, 2011–15. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, vii5-vii11.	3.0	17
198	Real-life experience with ceftobiprole in Canada: Results from the CLEAR (CanadianLeadership) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62	2.2	17

#	ARTICLE	IF	CITATIONS
199	Susceptibilities of <i>Candida</i> Species Isolated from the Lower Gastrointestinal Tracts of High-Risk Patients to the New Semisynthetic Echinocandin LY303366 and Other Antifungal Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 2446-2448.	3.2	16
200	The use of macrolides in treatment of upper respiratory tract infections. <i>Current Allergy and Asthma Reports</i> , 2006, 6, 171-181.	5.3	16
201	Characterization of <i>Acinetobacter baumannii</i> and meropenem-resistant <i>Pseudomonas aeruginosa</i> in Canada: results of the CANWARD 2007-2009 study. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 69, 335-341.	1.8	16
202	Development of dilipid polymyxins: Investigation on the effect of hydrophobicity through its fatty acyl component. <i>Bioorganic Chemistry</i> , 2018, 80, 639-648.	4.1	16
203	Trends in antimicrobial resistance over 10 years among key bacterial pathogens from Canadian hospitals: results of the CANWARD study 2007-16. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, iv22-iv31.	3.0	16
204	Polybasic peptide-levofloxacin conjugates potentiate fluoroquinolones and other classes of antibiotics against multidrug-resistant Gram-negative bacteria. <i>MedChemComm</i> , 2019, 10, 517-527.	3.4	16
205	Identification of a novel metallo- β -lactamase, CAM-1, in clinical <i>Pseudomonas aeruginosa</i> isolates from Canada. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1563-1567.	3.0	16
206	Ketolides in the treatment of respiratory infections. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 277-297.	1.8	15
207	The use of macrolides in treatment of upper respiratory tract infections. <i>Current Infectious Disease Reports</i> , 2005, 7, 175-184.	3.0	15
208	Introduction to the CANWARD study (2007-11). <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, i3-i5.	3.0	15
209	Development of a nebramine-cyclam conjugate as an antibacterial adjuvant to potentiate β -lactam antibiotics against multidrug-resistant <i>P. aeruginosa</i> . <i>Journal of Antibiotics</i> , 2019, 72, 816-826.	2.0	15
210	Antimicrobial susceptibility of <i>Clostridioides difficile</i> isolated from diarrhoeal stool specimens of Canadian patients: summary of results from the Canadian <i>Clostridioides difficile</i> (CAN-DIFF) surveillance study from 2013 to 2017. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1824-1832.	3.0	15
211	Antibiotic and Oral Contraceptive Drug Interactions: Is There a Need for Concern?. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 1999, 10, 429-433.	0.3	14
212	Are fluoroquinolone-susceptible isolates of <i>Streptococcus pneumoniae</i> really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 769-772.	3.0	14
213	Prevalence of Antimicrobial-Resistant Pathogens in Canadian Hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2007). <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2009, 20, 9A-19A.	1.9	14
214	In vitro susceptibility of urinary <i>Escherichia coli</i> isolates to first- and second-line empirically prescribed oral antimicrobials: CANWARD surveillance study results for Canadian outpatients, 2007-2016. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 62-68.	2.5	14
215	Status Report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society: Part 1: Antibiotic Prescribing Patterns, Sources of Antibiotic Exposure, Antibiotic Consumption and Emergence of Antibiotic Resistance, Impact of Alterations in Antibiotic Prescribing, and Clinical Sequelae of Antibiotic Use. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2016, 9, 18-24.	0.1	14
216	Call for the international adoption of microbiological breakpoints for fluoroquinolones and <i>Streptococcus pneumoniae</i> . <i>International Journal of Antimicrobial Agents</i> , 2006, 28, 266-269.	2.5	12

#	ARTICLE	IF	CITATIONS
217	Oral and Intravenous Fosfomycin for the Treatment of Complicated Urinary Tract Infections. Canadian Journal of Infectious Diseases and Medical Microbiology, 2020, 2020, 1-11.	1.9	12
218	Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria. Drugs, 2022, 82, 533-557.	10.9	12
219	Pharmacokinetics/pharmacodynamics of levofloxacin 750mg once daily in young women with acute uncomplicated pyelonephritis. International Journal of Antimicrobial Agents, 2008, 31, 287-289.	2.5	11
220	Introduction to the CANWARD Study (2007-2009). Diagnostic Microbiology and Infectious Disease, 2011, 69, 289-290.	1.8	11
221	Comparison of <i>In Vivo</i> and <i>In Vitro</i> Pharmacodynamics of a Humanized Regimen of 600 Milligrams of Ceftaroline Fosamil Every 12 Hours against Staphylococcus aureus at Initial Inocula of 10 ⁶ and 10 ⁸ CFU per Milliliter. Antimicrobial Agents and Chemotherapy, 2014, 58, 6931-6933.	3.2	11
222	A Dimer, but Not Monomer, of Tobramycin Potentiates Ceftolozane against Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa and Delays Resistance Development. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	11
223	In Vitro Activities of Six Fluoroquinolones against Canadian Isolates of Vancomycin-sensitive and Vancomycin-resistant Enterococcus species. Diagnostic Microbiology and Infectious Disease, 1998, 31, 343-347.	1.8	10
224	Mecillinam Activity Compared to Ampicillin, Trimethoprim/Sulfamethoxazole, Ciprofloxacin and Nitrofurantoin against Urinary Tract Isolates of Gram-Negative Bacilli. Chemotherapy, 1998, 44, 391-396.	1.6	10
225	Levofloxacin for the treatment of community-acquired pneumonia. Expert Review of Anti-Infective Therapy, 2006, 4, 725-742.	4.4	10
226	Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum β -lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model. Journal of Antimicrobial Chemotherapy, 2014, 69, 2448-2452.	3.0	10
227	<i>In Vitro</i> Activity of Ceftazidime-Avibactam against 338 Molecularly Characterized Gentamicin-Nonsusceptible Gram-Negative Clinical Isolates Obtained from Patients in Canadian Hospitals. Antimicrobial Agents and Chemotherapy, 2015, 59, 3623-3626.	3.2	10
228	In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015. Diagnostic Microbiology and Infectious Disease, 2017, 87, 349-356.	1.8	10
229	<i>In vitro</i> activity and resistance rates of topical antimicrobials fusidic acid, mupirocin and ozenoxacin against skin and soft tissue infection pathogens obtained across Canada (CANWARD) Tj ETQq1 1 0.784314 rgBT1/Overlo		
230	Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007-19. JAC-Antimicrobial Resistance, 2022, 4, dlab197.	2.1	10
231	Comparison of Community-Associated and Health Care-Associated Methicillin-Resistant <i>Staphylococcus aureus</i> in Canada: Results from CANWARD 2007. Canadian Journal of Infectious Diseases and Medical Microbiology, 2009, 20, 31A-36A.	1.9	9
232	Modulation of the Local Neutrophil Response by a Novel Hyaluronic Acid-Binding Peptide Reduces Bacterial Burden during Staphylococcal Wound Infection. Infection and Immunity, 2010, 78, 4176-4186.	2.2	9
233	Synthesis and antibacterial properties of carbohydrate-templated lysine surfactants. Carbohydrate Research, 2011, 346, 588-594.	2.3	9
234	Identification and Characterization of a Novel FosA7 Member from Fosfomycin-Resistant Escherichia coli Clinical Isolates from Canadian Hospitals. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	9

#	ARTICLE	IF	CITATIONS
235	Antiseptic quaternary ammonium compound tolerance by gram-negative bacteria can be rapidly detected using an impermeant fluorescent dye-based assay. <i>Scientific Reports</i> , 2020, 10, 20543.	3.3	9
236	Characterization of Proteobacterial Plasmid Integron-Encoded <i>qac</i> Efflux Pump Sequence Diversity and Quaternary Ammonium Compound Antiseptic Selection in <i>Escherichia coli</i> Grown Planktonically and as Biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0106921.	3.2	9
237	Linear Regression Equations To Predict \hat{I}^2 -Lactam, Macrolide, Lincosamide, and Fluoroquinolone MICs from Molecular Antimicrobial Resistance Determinants in <i>Streptococcus pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0137021.	3.2	9
238	Status Report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society: Part 3: Current Perspectives on Skin and Soft Tissue Infections with Emphasis on Methicillin-resistant <i>Staphylococcus aureus</i> , Commonly Encountered Scenarios when Antibiotic Use May Not Be Needed, and Concluding Remarks on Rational Use of Antibiotics in Dermatology. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2016, 9, 17-24.	0.1	9
239	<i>In Vitro</i> Activity of Cefiderocol against Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> : CANWARD, 2007 to 2019. <i>Microbiology Spectrum</i> , 2022, 10, .	3.0	9
240	Effect of interventions on prescribing of antimicrobials for prophylaxis in obstetric and gynecologic surgery. <i>American Journal of Health-System Pharmacy</i> , 1989, 46, 2493-2496.	1.0	8
241	Ribosomal resistance: Emerging problems and potential solutions. <i>Current Infectious Disease Reports</i> , 1999, 1, 458-463.	3.0	8
242	Riboswitch-Associated Guanidinium-Selective Efflux Pumps Frequently Transmitted on Proteobacterial Plasmids Increase <i>Escherichia coli</i> Biofilm Tolerance to Disinfectants. <i>Journal of Bacteriology</i> , 2020, 202, .	2.2	8
243	Susceptibility of Clinical Isolates of <i>Escherichia coli</i> to Fosfomycin as Measured by Four <i>In Vitro</i> Testing Methods. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	8
244	ESBL-positive <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> isolates from across Canada: CANWARD surveillance study, 2007-18. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2815-2824.	3.0	8
245	Phenotypic and Multi-Omics Characterization of <i>Escherichia coli</i> K-12 Adapted to Chlorhexidine Identifies the Role of MlaA and Other Cell Envelope Alterations Regulated by Stress Inducible Pathways in CHX Resistance. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 659058.	3.5	8
246	<i>In vitro</i> activity of imipenem-relebactam against various resistance phenotypes/genotypes of Enterobacterales and <i>Pseudomonas aeruginosa</i> isolated from patients across Canada as part of the CANWARD study, 2016-2019. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 101, 115418.	1.8	8
247	Antibacterial Drivers of Resistance. <i>Treatments in Respiratory Medicine</i> , 2005, 4, 13-18.	1.4	7
248	Genetic relatedness of multidrug-resistant <i>Escherichia coli</i> cultured from geographically diverse outpatient, midstream urine specimens. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 58, 283-287.	1.8	7
249	Selection of <i>agyrA</i> mutation and Treatment Failure with Gatifloxacin in a Patient with <i>Streptococcus pneumoniae</i> with a Preexisting <i>parC</i> mutation. <i>Pharmacotherapy</i> , 2007, 27, 221-226.	2.6	7
250	<i>In vitro</i> activity of the investigational ketolide cethromycin against macrolide- and penicillin-resistant <i>Streptococcus pneumoniae</i> : review of the 1998 to 2006 Canadian Respiratory Organism Susceptibility Study (CROSS). <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 620-622.	3.0	7
251	Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy. <i>Drug, Healthcare and Patient Safety</i> , 2011, 3, 59.	2.5	7
252	<i>In vitro</i> potency and combination testing of antimicrobial agents against <i>Neisseria gonorrhoeae</i> . <i>Journal of Infection and Chemotherapy</i> , 2016, 22, 194-197.	1.7	7

#	ARTICLE	IF	CITATIONS
253	Cost-Effectiveness Analysis of Fosfomycin for Treatment of Uncomplicated Urinary Tract Infections in Ontario. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2017, 2017, 1-11.	1.9	7
254	Comparison of PCV-10 and PCV-13 vaccine coverage for invasive pneumococcal isolates obtained across Canadian geographic regions, SAVE 2011 to 2017. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 99, 115282.	1.8	7
255	Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian) Tj ETQq1 1 0.784314 rgBT /Overlock 25, 346-350.	2.2	7
256	Use of Fosfomycin Etest To Determine <i>In Vitro</i> Susceptibility of Clinical Isolates of <i>Enterobacterales</i> Other than <i>Escherichia coli</i> , Nonfermenting Gram-Negative Bacilli, and Gram-Positive Cocci. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0163521.	3.9	7
257	Invasive pneumococcal disease caused by serotypes 22F and 33F in Canada: the SAVE study 2011–2018. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 101, 115447.	1.8	7
258	<i>Pseudomonas aeruginosa</i> Pneumonia: Evolution of Antimicrobial Resistance and Implications for Therapy. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2022, 43, 191-218.	2.1	7
259	Low Prevalence of Gastrointestinal Colonization with Antimicrobial-Resistant Bacteria in High Risk Units in a Canadian Tertiary Care Centre. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 1996, 7, 307-312.	0.3	6
260	<i>In Vitro</i> Activity of Iclaprim against Respiratory and Bacteremic Isolates of <i>Streptococcus pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1690-1692.	3.2	6
261	Fluoroquinolone resistance in <i>Escherichia coli</i> isolated from patients attending Canadian hospitals is associated with the ST131 clone. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 71, 323-324.	1.8	6
262	Pharmacodynamic Profiling of Antimicrobials against Gram-negative Respiratory Isolates from Canadian Hospitals. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2011, 22, 132-136.	1.9	6
263	Antimicrobial susceptibility of <i>Pseudomonas aeruginosa</i> isolates obtained from patients in Canadian hospitals: CANWARD 2008–2011. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 73, 361-364.	1.8	6
264	Pharmacodynamic activity of fosfomycin simulating urinary concentrations achieved after a single 3-g oral dose versus <i>Escherichia coli</i> using an <i>in vitro</i> model. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 88, 271-275.	1.8	6
265	Whole genome characterization of <i>Streptococcus pneumoniae</i> from respiratory and blood cultures collected from Canadian hospitals before and after PCV-13 implementation in Canada: Focus on serotypes 22F and 33F from CANWARD 2007–2018. <i>Vaccine</i> , 2021, 39, 5474-5483.	3.8	6
266	Comparison of CO ₂ Generation (BACTEC) and Viable-Count Methods To Determine the Postantibiotic Effect of Antimycobacterial Agents against <i>Mycobacterium avium</i> Complex. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 184-187.	3.2	6
267	The use of ketolides in treatment of upper respiratory tract infections. <i>Current Infectious Disease Reports</i> , 2004, 6, 191-199.	3.0	5
268	Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant <i>Streptococcus pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 112-116.	3.0	5
269	Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of <i>Escherichia coli</i> with extended-spectrum β -lactamases, AmpC β -lactamases and reduced susceptibility to carbapenems using an <i>in vitro</i> model. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 824-828.	3.0	5
270	Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant <i>Streptococcus pneumoniae</i> with elevated MICs of ceftaroline using an <i>in vitro</i> pharmacodynamic model. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1706-1711.	3.0	5

#	ARTICLE	IF	CITATIONS
271	Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant <i>Streptococcus pneumoniae</i> : analysis of Phase 3 clinical trial data—authors' response: Figure 1.. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3170.2-3171.	3.0	5
272	Fosfomycin Trometamol for the Prevention of Infectious Complications After Prostate Biopsy: A Consensus Statement by an International Multidisciplinary Group. <i>European Urology Focus</i> , 2022, 8, 1483-1492.	3.1	5
273	A short communication article: A <i>Clostridioides difficile</i> surveillance study of Canadian retail meat samples from 2016 to 2018. <i>Anaerobe</i> , 2022, , 102551.	2.1	5
274	Ciprofloxacin or Imipenem Use Correlates with Resistance in <i>Pseudomonas aeruginosa</i> . <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 1998, 9, 382-386.	0.3	4
275	Low Prevalence of VRE Gastrointestinal Colonization of Hospitalized Patients in Manitoba Tertiary Care and Community Hospitals. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 2000, 11, 38-41.	0.3	4
276	Predictors of receipt of a fluoroquinolone versus trimethoprim-sulfamethoxazole for treatment of acute pyelonephritis in women in Manitoba, Canada. <i>Pharmacoepidemiology and Drug Safety</i> , 2004, 13, 863-870.	1.9	4
277	Stability of Fluoroquinolone Resistance in <i>Streptococcus pneumoniae</i> Clinical Isolates and Laboratory-Derived Mutants. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 846-848.	3.2	4
278	Pharmacodynamic activity of ertapenem versus multidrug-resistant genotypically characterized extended-spectrum β -lactamase-producing <i>Escherichia coli</i> using an in vitro model. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 643-646.	3.0	4
279	Frequency of 16S ribosomal RNA methyltransferase detection among <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> clinical isolates obtained from patients in Canadian hospitals (CANWARD, 2013–2017). <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 199-201.	1.8	4
280	Comparison of phenotypic antimicrobial susceptibility testing results and WGS-derived genotypic resistance profiles for a cohort of ESBL-producing <i>Escherichia coli</i> collected from Canadian hospitals: CANWARD 2007–18. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2825-2832.	3.0	4
281	Community-Acquired Pneumonia in Canada During Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac043.	0.9	4
282	Applying fluorescent dye assays to discriminate <i>Escherichia coli</i> chlorhexidine resistance phenotypes from porin and <i>miaA</i> deletions and efflux pumps. <i>Scientific Reports</i> , 2022, 12, .	3.3	4
283	Antimicrobial-Resistant <i>Streptococcus pneumoniae</i> in Canadian Hospitals: Results from the 2007 CANWARD Study. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2009, 20, 37A-42A.	1.9	3
284	Prevalence and Characterization of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Isolated in Canadian Hospitals: Results from CANWARD 2007. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2009, 20, 43A-48A.	1.9	3
285	Kisameet Clay Isolated from the Central Coast of British Columbia, Canada, Demonstrates Broad-Spectrum Antimicrobial Activity. <i>MBio</i> , 2016, 7, e00169.	4.1	3
286	Ten years of the CANWARD Study (2007–16). <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, iv2-iv4.	3.0	3
287	Risk versus Benefit of Using Hydroxychloroquine to Treat Patients with COVID-19. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2021, 2021, 1-7.	1.9	3
288	Infections Due to <i>Acinetobacter baumannii</i> – <i>calcoaceticus</i> Complex: Escalation of Antimicrobial Resistance and Evolving Treatment Options. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2022, 43, 097-124.	2.1	3

#	ARTICLE	IF	CITATIONS
289	Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible <i>Streptococcus pneumoniae</i> using an in vitro model. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 59, 144-147.	3.0	2
290	Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical <i>Streptococcus pneumoniae</i> isolates, including molecularly characterized ciprofloxacin-resistant isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 202-204.	3.0	2
291	Analysis of 1560 Inpatient and Outpatient <i>Escherichia coli</i> isolates from across Canada—Results from the CANWARD 2007 Study. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2009, 20, 49A-53A.	1.9	2
292	Mutant Prevention Concentrations of Doripenem and Meropenem Alone and in Combination with Colistin (Polymyxin E), Levofloxacin and Tobramycin in <i>Pseudomonas aeruginosa</i> . <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2009, 20, 67A-71A.	1.9	2
293	Introduction to the SAVE study (2011–15): <i>Streptococcus pneumoniae</i> serotyping and antimicrobial susceptibility: Assessment for Vaccine Efficacy in Canada after the introduction of PCV-13. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, vii2-vii4.	3.0	2
294	Fosfomycin resistance mediated by fos genes remains rare among extended-spectrum beta-lactamase-producing <i>Escherichia coli</i> clinical isolates recovered from the urine of patients evaluated at Canadian hospitals (CANWARD, 2007–2017). <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 96, 114962.	1.8	2
295	Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia. <i>Therapeutics and Clinical Risk Management</i> , 2006, 2, 59-75.	2.0	2
296	Activity of Dapsone versus Community and Hospital Pathogens from the CANWARD Study. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2016, 9, 42-7.	0.1	2
297	PCV-15 and PPSV-23 coverage of invasive and respiratory tract <i>Streptococcus pneumoniae</i> , including MDR and XDR isolates: CANWARD 2007–20. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1444-1451.	3.0	2
298	In vitro activity of garenoxacin, a novel des-F(6)-fluoroquinolone. <i>Clinical Microbiology Newsletter</i> , 2003, 25, 153-159.	0.7	1
299	Launching of the CAN-R Web Site – The Official Web Site of the Canadian Antimicrobial Resistance Alliance. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2007, 18, 151-152.	1.9	1
300	Pharmacokinetics and pharmacodynamics (PK/PD) of fluoroquinolones: tools for combating bacteria and preventing resistance. <i>Milestones in Drug Therapy</i> , 2003, , 87-105.	0.1	1
301	Fluoroquinolone AUC Break Points and the Link to Bacterial Killing Rates: In Vitro Models. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1331-1334.	1.9	0
302	Ciprofloxacin Extended Release. <i>Drugs and Aging</i> , 2004, 21, 65-66.	2.7	0
303	Key Research Issues in <i>Clostridium difficile</i> . <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2005, 16, 282-285.	1.9	0
304	Introduction to CANWARD 2007. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2009, 20, 7A-8A.	1.9	0
305	254 In Vitro Activity of Ceftazidime in Combination with Avibactam vs 1825 <i>Pseudomonas aeruginosa</i> Clinical Isolates Obtained from across Canada as Part of the CANWARD Study, 2009-2013. <i>Open Forum Infectious Diseases</i> , 2014, 1, S109-S109.	0.9	0
306	In Vitro Activity of Newer Antimicrobials and Relevant Comparators Vs. 349 <i>Stenotrophomonas maltophilia</i> Clinical Isolates Obtained from Patients in Canadian Hospitals (CANWARD, 2011–2016). <i>Open Forum Infectious Diseases</i> , 2017, 4, S367-S368.	0.9	0

#	ARTICLE	IF	CITATIONS
307	In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible <i>Pseudomonas aeruginosa</i> Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016. <i>Open Forum Infectious Diseases</i> , 2017, 4, S372-S372.	0.9	0
308	2383. <i>In Vitro</i> Activity of Ceftolozane–Tazobactam in Comparison With Ceftazidime–Avibactam vs. Antimicrobial Non-Susceptible <i>Pseudomonas aeruginosa</i> Clinical Isolates, Including Multidrug-Resistant and Extensively Drug-Resistant Subsets: CANWARD, 2007–2017. <i>Open Forum Infectious Diseases</i> , 2018, 5, S710-S710.	0.9	0
309	708. In Vitro Activity of Plazomicin vs. Clinical Isolates of Gram-Negative Bacilli, Including Aminoglycoside Nonsusceptible and Multidrug-Resistant Subsets, Recovered from Patients Across Canada as Part of the CANWARD study, 2011–2018. <i>Open Forum Infectious Diseases</i> , 2019, 6, S319-S319.	0.9	0
310	128. Adequacy of Commonly Prescribed Antimicrobials for Empiric Coverage of Gram-Negative Bacterial Pathogens Recovered from the Bloodstream of Patients Attending Emergency Rooms in Canada: Analysis of Data from the CANWARD Study, 2007 to 2018. <i>Open Forum Infectious Diseases</i> , 2019, 6, S93-S93.	0.9	0
311	In vitro susceptibility of common bacterial pathogens causing respiratory tract infections in Canada to lefamulin, a new pleuromutilin. <i>Jammi</i> , 2021, 6, 149-162.	0.5	0
312	Fluoroquinolone Resistance–Associated Gene Mutations in <i>Streptococcus pneumoniae</i> . , 2004, , 496-499.		0